Entrada Therapeutics (TRDA) Current Leases (2022 - 2025)
Historic Current Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $4.4 million.
- Entrada Therapeutics' Current Leases fell 4378.39% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 4378.39%. This contributed to the annual value of $7.6 million for FY2024, which is 442.53% down from last year.
- Latest data reveals that Entrada Therapeutics reported Current Leases of $4.4 million as of Q3 2025, which was down 4378.39% from $5.5 million recorded in Q2 2025.
- Entrada Therapeutics' Current Leases' 5-year high stood at $8.6 million during Q2 2024, with a 5-year trough of $4.4 million in Q3 2025.
- Its 4-year average for Current Leases is $7.4 million, with a median of $7.7 million in 2024.
- In the last 5 years, Entrada Therapeutics' Current Leases soared by 1686.61% in 2024 and then tumbled by 4378.39% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' Current Leases stood at $8.4 million in 2022, then decreased by 5.91% to $7.9 million in 2023, then decreased by 4.43% to $7.6 million in 2024, then crashed by 42.45% to $4.4 million in 2025.
- Its Current Leases was $4.4 million in Q3 2025, compared to $5.5 million in Q2 2025 and $6.5 million in Q1 2025.